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Objective: To determine whether postoperative adjuvant chemotherapy 
confers a survival benefit on patients with esophageal squamous cell 
carcinoma undergoing radical surgery, we undertook a cooperative, pro- 
spective randomized controlled trial. Methods: A total of 205 patients 
underwent transthoracic esophagectomy with lymphadenectomy at eleven 
institutions between December 1988 and July 1991. These patients were 
prospectively randomized into two groups (100 patients underwent surgery 
alone and 105 patients had additional two courses of combination chemo- 
therapy with cisplatin (70 mg/m 2) and vindesine (3 rag/m2). The two groups 
did not differ with respect to sex, age, location of tumor, and distributions 
of pT, pN, pM, or p stage. Results: The 5-year survival was 44.9% in the 
surgery alone group and 48.1% in the surgery plus chemotherapy group. 
The relative risk was estimated to be 0.89 (95% confidence interval, 0.61 to 
1.31) in the surgery plus chemotherapy group compared with the surgery 
alone group. No significant differences in survival were detected between 
the two groups, even with lymph node stratification. Conclusion: Postoper- 
ative adjuvant chemotherapy with cisplatin and vindesine has no additive 
effect on survival in patients with esophageal cancer compared with surgery 
alone. (J Thorac Cardiovasc Surg 1997;114:205-9) 
S ince 1978, the Japan Esophageal Oncology Group ( JEOG),  a subgroup of the Japan Clinical 
Oncology Group ( JCOG),  has developed adjuvant 
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therapeutic modalities for esophageal cancer using 
randomized controlled trials. I' 2 These studies have 
shown an improvement in survival that can be 
attributed to recent advances in esophageal cancer 
surgery, 2 in particular cervical-upper mediastinal 
lymphadenectomy. 3 This site had been previously 
identified as the most frequent site of cancer recur- 
rence. Thus in Japan a transthoracic esophagectomy 
with extensive lymphadenectomy is now regarded as 
the standard treatment for patients with cancer of 
the thoracic esophagus. 
Adjuvant chemotherapy for esophageal cancer, 
however, remains investigational. 4' 5 This study was 
designed to determine whether postoperative adju- 
vant chemotherapy confers a survival benefit on 
patients undergoing a transthoracic esophagectomy 
with lymphadenectomy for cancer of the thoracic 
esophagus. Surgery alone was compared with post- 
operative adjuvant chemotherapy in a multicenter 
trial. 
Patients and methods 
The study was composed of patients who were sched- 
uled to undergo transthoracic curative resection of an 
esophageal tumor including complete removal of the 
primary lesion and dissection of the regional and distant 
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Table I. Characteristics of eligible patients 
Group A: Group B: 
Characteristic Surgery alone Surgery + CT 
Entered 100 i05 
Eligible 100 105 
Sex 
Male 92 90 
Female 8 15 
Age (yr) 
Range 39-75 40-75 
Mean (SD) 59.8 (8.3) 60.4 (9.6) 
No. of CT courses 
0 100 3 
1 14 
2 88 
CT, Chemotherapy; SD, standard eviation. 
lymph nodes, with esophagogastric or esophagocolic anas- 
tomosis in the neck. The regional ymphadenectomy in- 
cluded not only the mediastinal but also the perigastric 
nodes. The distant lymphadenectomy included cervical or 
celiac nodes, or both. 
These patients were prospectively randomized into two 
groups: surgery alone (group A) and surgery plus postop- 
erative chemotherapy (group B). Selection was performed 
by block randomization using the number of patients as 
the blocking factor within 2 months of the operationl In 
group B, cisplatin (70 mg/m 2) was given by slow drip 
infusion and vindesine (3 mg/m ~) was given by intravenous 
bolus infusion on days 1 and 21. Chemotherapy was to be 
repeated twice at intervals of 3 weeks. This study was 
reviewed and approved by the review boards of all eleven 
institutions. Patients were entered into this study accord- 
ing to the following eligibility criteria: (1) histologically 
proved squamous cell carcinoma of the thoracic esopha- 
gus, (2) tumor invasion into and beyond the submucosal 
layer (->Tlb6), (3) age younger than 75 years, and (4) 
normal clinical laboratory profile (white blood count -> 
4000/ram 3, hemoglobin value -> 10 gm/dl, platelet count >- 
100,000/ram 3, aspartate aminotransferase and alanine 
aminotransferase less than twice normal, creatinine -< 1.2 
mg/dl, creatinine clearance -> 60 ml/min, blood urea 
nitrogen -< 25 mg/dl, arterial oxygen tension -> 70 mm Hg, 
and vital capacity -> 1500 ml). Informed consent was 
obtained from all patients before treatment. Eligible 
patients were stratified depending on the presence of 
pathologic lymph node metastasis, the most important 
prognostic factor. 
The second course of chemotherapy was halted if the 
white blood count fell to less than 2000/ram 3, platelet 
count fell to less than 50,000/ram 3, creatinine concentra- 
tion rose to greater than 1.5 mg/dl, creatinine clearance 
fell to less than 40 ml/min, or if blood urea nitrogen rose 
to more than 25 mg/dl. The dose of cisplatin was de- 
creased by 50% in cases in which creatinine concentration 
was between 1.2 and 1.5 mg/dl or creatinine clearance was 
between 40 and 60 ml/min. The dose of vindesine was 
decreased by 50% in cases in which the white blood count 
was between 2000 and 4000/ram 3 or the platelet count 
between 50,000 and 100,000/mm 3. 
The sample size was calculated to detect an increase 
from 40% to 60% in the 5-year survival at a significance 
level a = 5% and a power of 80%. Therefore at least 98 
patients per treatment group were required. Patient char- 
acteristics were examined to identify differences between 
any two groups by means of the )(2 test. Side effects after 
postoperative treatment were classified according to the 
JCOG toxicity criteria. 7 Prognosis was evaluated 44 
months after the end of case entry. Survival analysis was 
performed by means of the Kaplan-Meier method. Sur- 
vival curves were compared by means of the log rank and 
generalized Wilcoxon tests. The relative risk was esti- 
mated by Cox's regression model. Cancer recurrence was 
identified locally in the cervical lymph nodes, the medias- 
tinal lymph nodes, the abdominal lymph nodes, the lung, 
liver, bone, or kidney. The distribution of the sites of 
recurrence was compared between the two groups by 
means of the X 2 test. All calculations were performed with 
SAS software (SAS Institute, Inc., Cary, N.C.) on a UNIX 
computer in the Statistics Center of the JCOG. Clinico- 
pathologic parameters were characterized according to 
the TNM classification of the International Union Against 
Cancer (UICC). 6 
Results 
From December 10, 1988, to July 10, 1991, 205 
patients were entered into this study (100 in group A 
and 105 in group B). They comprised 23.5% (205/ 
872) of all of the patients with esophageal cancer 
undergoing resection at the involved institutions 
during the study period. No statistically significant 
differences were observed in the male/female ratio 
or the age distribution between the groups (Table I). 
In group B, 17 patients were not able to complete 
the postoperative chemotherapy course. Of these 
patients, 14 underwent only one course of chemo- 
therapy because of side effects or patient refusal of 
further treatment. Three patients were not able to 
undergo chemotherapy, two owing to relapse of 
postoperative pneumonia and one owing to liver 
dysfunction. No statistically significant differences 
were present between the two groups with respect o 
the location of the tumor or pT, pN, pM, and p stage 
classification (Table II). 
Grade 3 side effects were manifest by decreased 
hemoglobin level (n = 2), decreased white blood 
count (n = 11), nausea/vomiting (n = 13), diarrhea 
(n = 1), elevated serum creatinine concentration 
(n = 5), or infection (n = 1). Grade 4 side effects 
were manifest by decreased white blood count (n = 
2), diarrhea (n = 1), or elevated serum creatinine 
concentration (n = 3). 
The median follow-up period was 59.2 months 
(range 42.8 to 74.8 months). No significant differ- 
ence in survival was observed between the two 
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groups (log rank test, p = 0.55; Wilcoxon test, p = 
0.60) (Fig. 1). The 5-year survivals were 45.1% (95% 
confidence interval [CI], 35.2% to 55.1%) in group 
A and 48.3% (95% CI, 38.2% to 58.3%) in group B. 
The relative risk estimate of group B against group 
A was 0.89 (95% CI, 0.61 to 1.31), and it was 0.84 
(95% CI, 0.57 to 1.24) after adjustment of poten- 
tially confounding factors uch as sex, age, location, 
pT, pN, and pM. In the subgroups with negative 
nodes (pN0), the 5-year survivals were 72.4% (95% 
CI, 54.9% to 89.9%) in group A and 60.3% (95% 
CI, 42.0% to 78.6%) in group B. No significant 
difference was observed between the two groups 
(log rank test, p = 0.26; Wilcoxon test, p = 0.20). 
The relative risk was 1.71 (95% CI, 0.66 to 4.42). In 
group A, no patients died within 1 year of the 
operation. In group B, six patients died within 1 year 
of the operation. Four of these were not cancer- 
related deaths (pneumonia, n = 1; ileus, n = 1; 
traffic accident, n = 1; and suicide, n = 1). 
In the subgroups with positive nodes (pN1), the 
5-year survivals were 35.5% (95% CI, 24.2% to 
46.6%) in group A and 43.7% (95% CI, 31.8% to 
55.6%) in group B. No significant difference was 
noted between the two groups (log rank test, p = 
0.15; Wilcoxon test, p = 0.13). The relative risk was 
0.74 (95% CI, 0.44 to 1.13). In the pN1 subgroups, 
survival was analyzed on the basis of the number of 
positive nodes. In the patients with three or fewer 
positive nodes (pNla), the 5-year survivals were 
49.8% (95% CI, 34.7% to 64.9%) in group A (n = 
45) and 60.6% (95% CI, 45.1% to 76.0%) in group 
B (n = 43). No significant difference was noted 
between the two groups (log rank test, p = 0.22; 
Wilcoxon test, p = 0.17). The relative risk was 0.67 
(95% CI, 0.35 to 1.28). In the patients with four or 
more positive nodes (pNlb, pNlc), the 5-year sur- 
vivals were 13.8% (95% CI, 1.3% to 26.3%) in group 
A (n = 29) and 21.2% (95% CI, 5.2% to 37.2%) in 
group B (n = 34). No significant difference was 
observed between the two groups (log rank test, p = 
0.21; Wilcoxon test, p = 0.32). The relative risk was 
0.71 (95% CI, 0.40 to 1.23). No significant difference 
was noted between the two groups with respect o 
the site of cancer ecurrence (Table III). 
Discussion 
The current state of the art of esophageal cancer 
surgery in Japan includes extensive lymphadenec- 
tomy including a three-field issection. Reported 
5-year survivals for patients undergoing a three-field 
lymphadenectomy (neck, mediastinum, and abdo- 
Table II. TNM classification of eligible patients 
Group A: Group B: 
TNM classification Surgery alone Surgery + CT X 2 Test 
Location of tumor 
Upper 8 7 p = 0.86 
Middle 59 60 
Lower 33 38 
pT 
T1 21 27 p = 0.30 
T2 16 11 
T3 56 64 
T4 7 3 
pN 
NO 26 28 p = 0.91 
N1 74 77 
pM 
M0 95 93 p = 0.10 
M1 LYM 5 12 
p Stage 
Stage I 10 12 p = 0.55 
Stage IIA 16 16 
Stage IIB 23 21 
Stage III 46 44 
Stage IV 5 12 
CT, Chemotherapy; LYM, lymph nodes. 
men) have been as high as 50%. s Even though a 
three-field issection improves urvival, 9' 10 its appli- 
cation is limited by the ability of the patient to 
tolerate the surgical stress. Therefore the develop- 
ment of effective multimodality treatment is ur- 
gently required. 
Since 1978, the JEOG has been developing adju- 
vant therapy for esophageal cancer using prospec- 
tive, randomized, controlled trials. The second 
phase III study (1981 to 1984) revealed that the 
5-year survival in the postoperative irradiation 
group was significantly higher than that in the 
preoperative plus postoperative irradiation group. 1
The third phase III study (1984 to 1987) was de- 
signed to compare postoperative irradiation (50 Gy) 
and postoperative combination chemotherapy with 
cisplatin and vindesine. This study revealed no sig- 
nificant difference in survival between the two 
groups. Although these results uggest that chemo- 
therapy had an effect on survival equivalent o 
postoperative irradiation, the results could also have 
been interpreted as demonstrating that neither post- 
operative chemotherapy nor irradiation had an im- 
pact on survival when compared with surgery alone. 
Even though the postoperative irradiation regimens 
in the second and third studies were the same, the 
5-year survival in the postoperative irradiation 
group in the third study (44%) was better than that 
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B : Surg + CT (n =105) 
A : Surg alone (n =100) 
0 12 24 38 48 80 72 84 
MONTHS 
Surg : surgery 
CT : chemotherapy  
P = .60 
Fig. 1. Survival curves for patients randomized to receive surgery plus chemotherapy or surgery alone, 
showing no significant difference between treatment groups. 
Table IlL Site of  cancer recurrence 
Group A: Group B: 
Site of recurrence Surgery alone Surgery + CT 
Local 3 0 
Cervical ymph nodes 11 10 
Mediastinal lymph nodes 9 12 
Abdominal lymph nodes 7 8 
Lung 7 9 
Liver 7 5 
Others 13 11 
CT, Chemotherapy. 
in the second study (33%). This difference may be 
explained by improvements in the dissection of the 
cervical-upper mediastinal nodes. 
After the surgical improvements, it again became 
important to study whether adjuvant chemotherapy 
after optimal surgical treatment had any additional 
impact on survival. The fourth phase III study (1988 
to 1991) was thus designed to compare surgery 
alone with surgery plus postoperative combination 
chemotherapy with cisplatin and vindesine. This is 
the same postoperative chemotherapy regimen used 
in the third phase III study. The JEOG phase II 
study of cisplatin and vindesine for patients with 
advanced esophageal cancer suggested that the che- 
motherapy used in this study had only a modest 
effect. In this phase II study, radiographic or endo- 
scopic evidence of a reduction in tumor size by 50% 
or more was seen in 16% 11 of patients (5/31). 
Although the chemotherapy doses were low by West- 
ern standards, only one treatment-related death oc- 
curred in the postoperative chemotherapy group in the 
third phase III study. Therefore the chemotherapy 
dose was consistent with general policies in Japan. 
No statistically significant differences were found 
in survival between the surgery alone and surgery 
plus postoperative chemotherapy groups, even with 
lymph node stratification. In the pN0 subgroups, the 
survival in group B was lower than that in group A 
because no early deaths occurred in group A (within 
1 year of the operation). On the other hand, six early 
deaths (within 1 year) occurred in group B (four of 
which were not cancer-related). It is unknown 
whether these deaths were attributed to the postop- 
erative chemotherapy. Recently, the number of pos- 
itive nodes has been identified as a prognostic factor 
in esophageal cancer. 3' 12 Even though the pN1 
subgroup was divided into pNla and pNlb depend- 
ing on the number of positive nodes, the differences 
in survival between groups A and B were not 
significant in any subgroups. 
On the basis of these data, we concluded that 
postoperative adjuvant chemotherapy with the use 
of a combination of cisplatin and vindesine has no 
additive effect on survival in patients with esopha- 
geal cancer compared with surgery alone. The 
present standard for chemotherapy in esophageal 
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cancer is a combination of cisplatin and 5-fluoro- 
uracil. 13 In the JEOG phase II study of cisplatin and 
5-fluorouracil in patients with advanced esophageal 
cancer, radiographic or endoscopic evidence of a 
reduction in tumor size by 50% or more was seen in 
36% 14 of patients (14/39). Therefore a prospective, 
randomized, controlled trial comparing surgery 
alone with postoperative adjuvant chemotherapy 
using cisplatin and 5-fluor0uracil is in the case entry 
phase. 
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